Physician profile
Katherine E Muniz
NPI 1073077608
$2,942.96
in general payments reported to CMS, 2019-2025
14 companies · $1,453 in 2025
The $1,453 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $311 · 2023: $513 · 2024: $667 · 2025: $1,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,264 · Travel and Lodging: $368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,264.36 |
| Travel and Lodging | $367.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $909.59 | 2023-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Cvrx, INC. | $621.29 | 2022-2025 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $478.96 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $402.75 | 2023-2025 | Camzyos, Eliquis |
| Nuwellis, INC. | $132.45 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $90.61 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $75.03 | 2024-2025 | Wainua, Farxiga |
| Abiomed | $50.93 | 2024 | Impella |
| Scpharmaceuticals INC. | $37.94 | 2023 | |
| Bridgebio Pharma, INC. | $36.71 | 2025 | Attruby |
| Kiniksa Pharmaceuticals International, Plc | $30.86 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $27.30 | 2023 | Onpattro |
| Merck Sharp & Dohme LLC | $24.80 | 2024 | Verquvo |
| Medtronic, INC. | $23.74 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Muniz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.